At Work With: Lisa Adler

Share this article:
Lisa Adler
Lisa Adler

LISA ADLER
VP, corporate communications,Millennium

What was your biggest break?

I was very fortunate to start off at two wonderful PR agencies in NYC (MS&L and Porter/Novelli) and given the opportunity to work on several new product launches.

What's the best and/or worst part of your job?

One of the many highlights of my position is being able to interact with patients and their families.

Who is the person you admire most in your area of work?

I had the privilege of working side-by-side with Millennium's former CEO, Dr. Deborah Dunsire, for eight years.

What's the view like from your office/work area?

From my office I can see some of the buildings on the MIT campus.

What are your favorite industry-related Web sites?

MyMultipleMyeloma.com is one of my favorites because it is a resource of information and hope. I am awfully proud of Millennium's involvement in its development.

Where will you be in five years?

I love working in this industry and the role I play at Millennium, and envision continuing along a similar path.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?